Stand Up To Cancer and Jazz Pharmaceuticals have entered into a three-year, $4 million research collaboration to research hard-to-treat cancers, including lurbinectedin in pediatric solid tumors and pan-RAF molecules in RAF- and RAS-mutated solid cancers.
Elizabeth Comen originally set out to write a book about the wellness industry, but ended up writing a different book altogether.
